Clinical Trials List
2021-12-01 - 2026-12-31
Phase III
Recruiting2
ICD-10C34.90
Malignant neoplasm of unspecified part of unspecified bronchus or lung
ICD-10C34.91
Malignant neoplasm of unspecified part of right bronchus or lung
ICD-10C34.92
Malignant neoplasm of unspecified part of left bronchus or lung
ICD-10C7A.090
Malignant carcinoid tumor of the bronchus and lung
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9162.9
Malignant neoplasm of bronchus and lung, unspecified
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Yi-Wei Chen Division of Radiation Therapy
- 趙恒勝 Division of Thoracic Medicine
- Chia-I Shen Division of Thoracic Medicine
- Hsu-ching Huang Division of Thoracic Medicine
- Yung-Hung Luo Division of Thoracic Medicine
- Chi-Lu Chiang Division of Thoracic Medicine
- YEN-HAN TSENG Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 李世俊 Division of Thoracic Surgery
- 林群書 Division of Radiation Therapy
- 張宏 Division of Thoracic Surgery
- 陳穎毅 Division of Thoracic Surgery
- 劉佳鑫 Division of Thoracic Medicine
- 羅承翔 Division of Radiation Therapy
- 吳悌暉 Division of Thoracic Surgery
- 林冠勳 Division of Thoracic Surgery
- 張山岳 Division of Thoracic Medicine
- 陳健文 Division of Thoracic Medicine
- 黃敍愷 Division of Thoracic Surgery
- 簡志峯 Division of Thoracic Medicine
- 沈志浩 Division of Thoracic Medicine
- 柯凱雄 Division of Radiology
- 郭彥劭 Division of Thoracic Surgery
- 彭忠衎 Division of Thoracic Medicine
- 蔡文銓 Division of Others
- 蘇瑜富 Division of Radiation Therapy
- 吳世偉 Division of Thoracic Medicine
- 孟繁俊 Division of Thoracic Medicine
- 唐士恩 Division of Thoracic Medicine
- 陳盈潔 Division of Thoracic Medicine
- 黃才旺 Division of Thoracic Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
8 participants
-
Global
530 participants